Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
54
About the Report
About the Report
Summary
Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at hematologic malignancies, and other tumors. The co-stimulatory antibodies harness human body's natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics' off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It has subsidiaries in the US, Germany, and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.
Heat Biologics Inc (HTBX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Heat Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises USD 5 Million In Venture Financing 13
Partnerships 14
Selexis and Pelican Therapeutics Enter into Agreement 14
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15
Licensing Agreements 16
University of Miami Enters into Licensing Agreement with Heat Biologics 16
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Equity Offering 22
Heat Biologics Files Registration Statement for Public Offering of Shares 22
Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23
Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24
Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27
Heat Biologics Raises USD7 Million in Public Offering of Shares 28
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30
Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD 27 Million 32
Acquisition 34
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34
Heat Biologics Inc-Key Competitors 35
Heat Biologics Inc-Key Employees 36
Heat Biologics Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 14, 2018: Heat Biologics reports second quarter 2018 results and provides corporate update 38
May 15, 2018: Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update 39
Feb 28, 2018: Heat Biologics Reports Fiscal Year 2017 Financial Results 40
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 41
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 42
Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 44
Corporate Communications 46
Feb 28, 2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards 46
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 47
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 48
Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 49
Product News 50
10/30/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its USD 15.2 Million CPRIT Grant Award 50
06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of USD 15.2 Million CPRIT Grant Award 51
03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 52
Clinical Trials 53
Nov 11, 2017: Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Figure
List of Figures
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises USD 5 Million In Venture Financing 13
Selexis and Pelican Therapeutics Enter into Agreement 14
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15
University of Miami Enters into Licensing Agreement with Heat Biologics 16
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Files Registration Statement for Public Offering of Shares 22
Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23
Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24
Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27
Heat Biologics Raises USD7 Million in Public Offering of Shares 28
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30
Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD 27 Million 32
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34
Heat Biologics Inc, Key Competitors 35
Heat Biologics Inc, Key Employees 36
Heat Biologics Inc, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.